Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a ---- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing
Prime Medicine got permission from the FDA to start testing a new medicine called PM577a that could help people with Wilson Disease. This is an important first step, but the company won't know if it actually works until they finish testing it in people around 2027.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.